A Phase I study showed that MassBiologics' experimental rabies treatment induced protective antibody levels in subjects comparable to those yielded by human rabies immune globulin, the standard rabies treatment. The treatment is being developed as an alternative to HRIG, which is costly and hard to access in developing countries. "The next step for clinical studies is already in the planning, and we are hopeful that this new therapy will have a major impact on rabies across the globe in the not too distant future," a researcher said.

Full Story:
Sify.com (India)

Related Summaries